Litcius/Paper detail

Nivolumab Plus Relatlimab: First Approval

Julia Paik

2022Drugs168 citationsDOIOpen Access PDF

Topics & Concepts

NivolumabMedicineMetastatic melanomaImmunotherapyOncologyMelanomaInternal medicineMonoclonal antibodyCombination therapyAntibodyPharmacologyCancerImmunologyCancer researchCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses
Nivolumab Plus Relatlimab: First Approval | Litcius